In a recent press release, Structure Therapeutics has reported encouraging topline results from its Phase 2 ACCESS clinical program evaluating aleniglipron, an investigational once-daily oral small-molecule glucagon-like peptide‑1 (GLP‑1) receptor agonist, in adults with obesity or overweight and at least one weight-related comorbidity. The data position aleniglipron as a potentially differentiated oral GLP‑1 option, demonstrating weight loss efficacy approaching that of injectable agents, alongside improved tolerability with optimized dosing strategies.
Strong efficacy signals in ACCESS II
The randomized, double-blind, placebo-controlled Phase 2 ACCESS II trial assessed higher doses of aleniglipron (up to 240 mg) over 44 weeks in 85 participants. At the study’s primary analysis, aleniglipron produced statistically significant and clinically meaningful reductions in body weight compared with placebo.
Participants receiving 180 mg and 240 mg achieved placebo-adjusted mean weight loss of approximately 16% at Week 44, corresponding to reductions of roughly 37–39 pounds. Importantly, weight loss continued through the end of the study without evidence of a plateau, a finding that supports the durability of the treatment effect at these higher oral doses.
Sustained weight loss beyond one year
Additional insight into longer-term efficacy came from the ACCESS open-label extension (OLE), which allowed participants to continue therapy beyond the initial randomized period. By 56 weeks, individuals treated with aleniglipron and titrated to a maximum dose of 120 mg maintained and extended their weight reduction, reaching average losses of just over 16% from baseline. As in ACCESS II, investigators did not observe a clear leveling off of weight loss over time.
These longer-duration results strengthen the case that aleniglipron may support sustained body weight reduction with chronic use.
Improved tolerability with lower starting dose
Across studies, aleniglipron’s safety and tolerability profile was broadly consistent with the GLP‑1 receptor agonist class, with gastrointestinal events—most commonly nausea and vomiting—reported most frequently, particularly during dose escalation.
Updated interim analyses from both the OLE and a dedicated body composition study suggest that beginning treatment at a lower 2.5 mg dose and titrating gradually may meaningfully reduce treatment discontinuations due to adverse events. With a median follow-up of approximately 20 weeks, adverse event–related discontinuation rates ranged from about 2% to 3.4% in these studies, which is lower than rates observed with higher starting doses in earlier trials.
Notably, in ACCESS II, among participants who reached doses of 120 mg or higher, only one discontinuation due to adverse events was reported during the later dosing period.
Body composition study supports early weight loss
The randomized, placebo-controlled body composition study enrolled 71 adults and focused on changes in fat mass while also evaluating tolerability with the lower starting dose. Interim findings showed that participants initiating therapy at 2.5 mg and titrating monthly achieved nearly 7% weight loss within approximately five months, while maintaining a manageable side effect profile. These data further support the optimized titration strategy planned for late-stage development.
Reassuring safety profile to date
Across more than 625 participants exposed to aleniglipron in the development program, the company has not reported cases of drug-induced liver injury, persistent liver enzyme elevations, or clinically meaningful QTc prolongation. No off-target safety signals have emerged thus far, supporting continued advancement of the molecule.
Path toward Phase 3 development
Based on the totality of Phase 2 evidence—spanning ACCESS, ACCESS II, the body composition study, and the ACCESS OLE—Structure Therapeutics plans to move aleniglipron into Phase 3 testing. An end-of-Phase 2 meeting with the US Food and Drug Administration is scheduled for the second quarter of 2026 to finalize trial design, including a low-dose initiation strategy and evaluation of multiple maintenance doses up to 240 mg.
If timelines remain on track, the company anticipates beginning Phase 3 studies in the second half of 2026.
Context in the evolving obesity treatment landscape
If confirmed in larger and longer-term trials, aleniglipron’s combination of injectable-like efficacy, oral administration, and comparatively low discontinuation rates could address key barriers to long-term obesity management. Investigators involved in the ACCESS program have highlighted the absence of a clear weight loss plateau through more than a year of therapy as a particularly encouraging signal.
As oral GLP‑1 therapies continue to be a major focus in metabolic disease research, aleniglipron’s Phase 2 results suggest it may emerge as a noteworthy contender pending validation in Phase 3 outcomes.
